Levin Capital Strategies L.P. Trims Holdings in Pfizer Inc. (PFE)

Levin Capital Strategies L.P. lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,567,404 shares of the biopharmaceutical company’s stock after selling 523,645 shares during the quarter. Pfizer makes up about 4.1% of Levin Capital Strategies L.P.’s investment portfolio, making the stock its 5th biggest position. Levin Capital Strategies L.P.’s holdings in Pfizer were worth $238,265,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Sarasin & Partners LLP lifted its stake in shares of Pfizer by 1.5% during the 2nd quarter. Sarasin & Partners LLP now owns 4,615,637 shares of the biopharmaceutical company’s stock worth $167,455,000 after purchasing an additional 69,794 shares during the period. Donaldson Capital Management LLC increased its holdings in shares of Pfizer by 0.8% during the 2nd quarter. Donaldson Capital Management LLC now owns 719,673 shares of the biopharmaceutical company’s stock worth $26,110,000 after buying an additional 5,385 shares during the last quarter. Girard Partners LTD. increased its holdings in shares of Pfizer by 1.5% during the 2nd quarter. Girard Partners LTD. now owns 105,631 shares of the biopharmaceutical company’s stock worth $3,832,000 after buying an additional 1,510 shares during the last quarter. Verity Asset Management Inc. increased its holdings in shares of Pfizer by 46.8% during the 2nd quarter. Verity Asset Management Inc. now owns 17,034 shares of the biopharmaceutical company’s stock worth $618,000 after buying an additional 5,429 shares during the last quarter. Finally, Savant Capital LLC increased its holdings in shares of Pfizer by 2.3% during the 2nd quarter. Savant Capital LLC now owns 58,512 shares of the biopharmaceutical company’s stock worth $2,123,000 after buying an additional 1,331 shares during the last quarter. 69.03% of the stock is currently owned by institutional investors.

In related news, VP Loretta V. Cangialosi sold 26,814 shares of the stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $40.16, for a total value of $1,076,850.24. Following the completion of the sale, the vice president now directly owns 102,360 shares in the company, valued at approximately $4,110,777.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 25,642 shares of the stock in a transaction on Friday, August 3rd. The shares were sold at an average price of $39.51, for a total value of $1,013,115.42. Following the completion of the sale, the insider now owns 127,954 shares of the company’s stock, valued at $5,055,462.54. The disclosure for this sale can be found here. Over the last quarter, insiders sold 234,096 shares of company stock valued at $9,366,617. 0.06% of the stock is owned by insiders.



A number of analysts have recently commented on PFE shares. Morgan Stanley set a $45.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Thursday, September 13th. Barclays restated a “neutral” rating and set a $40.00 price objective on shares of Pfizer in a report on Wednesday, September 26th. BMO Capital Markets restated a “buy” rating and set a $44.00 price objective on shares of Pfizer in a report on Monday, August 27th. Goldman Sachs Group restated a “neutral” rating and set a $45.00 price objective on shares of Pfizer in a report on Tuesday, August 28th. Finally, Credit Suisse Group set a $39.00 price objective on Pfizer and gave the stock a “hold” rating in a report on Tuesday, July 31st. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $42.80.

Shares of NYSE PFE opened at $42.60 on Friday. Pfizer Inc. has a 12-month low of $33.20 and a 12-month high of $45.81. The firm has a market capitalization of $258.41 billion, a P/E ratio of 16.08, a P/E/G ratio of 2.22 and a beta of 0.96. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.07. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The firm had revenue of $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. During the same period in the prior year, the firm earned $0.67 EPS. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be issued a $0.34 dividend. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.36 annualized dividend and a yield of 3.19%. Pfizer’s dividend payout ratio is currently 51.32%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Read More: What is a balanced fund?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply